CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


DeferoxamineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2534 Tocilizumab Injection Wiki 0.50
drug1978 Questionnaire Wiki 0.15

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D002386 Cataract NIH 0.71
D002318 Cardiovascular Diseases NIH 0.15

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0000518 Cataract HPO 0.71
HP:0001626 Abnormality of the cardiovascular system HPO 0.15

There are 2 clinical trials

Clinical Trials


1 Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations

In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.

NCT04333550 COVID-19 Drug: Deferoxamine

Primary Outcomes

Description: All cause of death

Measure: Mortality rate

Time: up to 20 days

Secondary Outcomes

Description: Mild, Moderate or Severe

Measure: change in patients clinical manifestation

Time: up to 20 days

Measure: change in patients PaO2

Time: up to 20 days

Description: days

Measure: Length of hospitalization

Time: up to 20 days

Measure: C-reactive protein

Time: up to 20 days

Measure: lymphocyte count

Time: up to 20 days

Measure: length of intensive care unit stay

Time: 1 to 20 days

2 Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.

NCT04361032 COVID19 Intensive Care Unit Drug: Tocilizumab Injection Drug: Deferoxamine

Primary Outcomes

Description: Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)

Measure: the mortality rate

Time: 90 day


No related HPO nodes (Using clinical trials)